Prof Randy Hecht talks to ecancer in an online interview about talimogene laherparepvec (T-VEC) and it's use in a recent trial presented at the ASCO 2020 virtual meeting.
Prof Hecht gives a thorough background on the use of T-VEC and it's use in oncology.
He then outlines the phase 1b, multi-centre, open-label, dose escalation study (NCT02509507) which evaluates the safety of intrahepatic injection of T-VEC in combination with intravenous pembrolizumab in patients with hepatocellular carcinoma or liver metastases.
Prof Hecht provides some throughs of the future potential of T-VEC and the next developments for this trial.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.